Browse > Article
http://dx.doi.org/10.5483/BMBRep.2019.52.9.113

6-sialyllactose ameliorates dihydrotestosterone-induced benign prostatic hyperplasia through suppressing VEGF-mediated angiogenesis  

Kim, Eun-Yeong (Department of Korean Medical Science, School of Korean Medicine, Pusan National University)
Jin, Bo-Ram (Department of Pharmacology, College of Korean Medicine, Sangji University)
Chung, Tae-Wook (Korean Medical Research Center for Healthy Aging, Pusan National University)
Bae, Sung-Jin (Korean Medical Research Center for Healthy Aging, Pusan National University)
Park, Hyerin (Department of Korean Medical Science, School of Korean Medicine, Pusan National University)
Ryu, Dongryeol (Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine)
Jin, Ling (Department of Korean Medical Science, School of Korean Medicine, Pusan National University)
An, Hyo-Jin (Department of Pharmacology, College of Korean Medicine, Sangji University)
Ha, Ki-Tae (Department of Korean Medical Science, School of Korean Medicine, Pusan National University)
Publication Information
BMB Reports / v.52, no.9, 2019 , pp. 560-565 More about this Journal
Abstract
Benign prostatic hyperplasia (BPH), a common disease in elderly males, is accompanied by non-malignant growth of prostate tissues, subsequently causing hypoxia and angiogenesis. Although VEGF-related angiogenesis is one of the therapeutic targets of prostate cancer, there is no previous study targeting angiogenesis for treatment of BPH. Dihydrotestosterone (DHT)-induced expressions of vascular endothelial growth factor (VEGF) in prostate epithelial RWPE-1 cells and human umbilical vascular endothelial cells (HUVECs). Conditioned media (CM) from DHT-treated RWPE-1 cells were transferred to HUVECs. Then, 6SL inhibited proliferation, VEGFR-2 activation, and tube formation of HUVECs transferred with CM from DHT-treated RWPE-1 cells. In the rat BPH model, 6SL reduced prostate weight, size, and thickness of the prostate tissue. Formation of vessels in prostatic tissues were also reduced with 6SL treatment. We found that 6SL has an ameliorative effect on in vitro and in vivo the BPH model via inhibition of VEGFR-2 activation and subsequent angiogenesis. These results suggest that 6SL might be a candidate for development of novel BPH drugs.
Keywords
Benign prostatic hyperplasia; Dihydrotestosterone; VEGF; VEGFR-2; 6-Siallylactose;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Emberton M, Andriole GL, de la Rosette J et al (2003) Benign prostatic hyperplasia: a progressive disease of aging men. Urology 61, 267-273   DOI
2 O'Leary MP (2003) Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology 62, 15-23   DOI
3 Keledjian K, Borkowski A, Kim G et al (2001) Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate 48, 71-78   DOI
4 Carson C 3rd, Rittmaster R (2003) The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61, 2-7   DOI
5 Zaman Huri H, Hui Xin C, Sulaiman CZ (2014) Drug-related problems in patients with benign prostatic hyperplasia: a cross sectional retrospective study. PLoS One 9, e86215   DOI
6 DuBeau CE, Resnick NM (1992) Controversies in the diagnosis and management of benign prostatic hypertrophy. Adv Intern Med 37, 55-83
7 Chung KJ, Chung BI (2017) Expected next-generation drugs under development in relation to voiding symptoms. Int Neurourol J 21, 97-101   DOI
8 McNeal JE (1978) Origin and evolution of benign prostatic enlargement. Invest Urol 15, 340-345
9 Lekas A, Lazaris AC, Deliveliotis C et al (2006) The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissue. Anticancer Res 26, 2989-2993
10 Wu F, Ding S, Li X et al (2016) Elevated expression of HIF-lalpha in actively growing prostate tissues is associated with clinical features of benign prostatic hyperplasia. Oncotarget 7, 12053-12062   DOI
11 Pareek G, Shevchuk M, Armenakas NA et al (2003) The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 169, 20-23   DOI
12 Stefanou D, Batistatou A, Kamina S, Arkoumani E, Papachristou DJ, Agnantis NJ (2004) Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In Vivo 18, 155-160
13 Aweimer A, Stachon T, Tannapfel A, Koller M, Truss MC, Stachon A (2012) Regulation of soluble VEGFR-2 secreted by microvascular endothelial cells derived from human BPH. Prostate Cancer Prostatic Dis 15, 157-164   DOI
14 Berger AP, Kofler K, Bektic J et al (2003) Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 57, 57-65   DOI
15 Levine AC, Liu XH, Greenberg PD et al (1998) Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 139, 4672-4678   DOI
16 Jackson MW, Bentel JM, Tilley WD (1997) Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157, 2323-2328   DOI
17 Lekas AG, Lazaris AC, Chrisofos M et al (2006) Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia. Urology 68, 436-441   DOI
18 Sordello S, Bertrand N, Plouet J (1998) Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 251, 287-290   DOI
19 Foo KT (2017) Pathophysiology of clinical benign prostatic hyperplasia. Asian J Urol 4, 152-157   DOI
20 Wen J, Zhao Y, Li J et al (2013) Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells. Prostate 73, 1069-1081   DOI
21 Wu S, Grimm R, German JB, Lebrilla CB (2011) Annotation and structural analysis of sialylated human milk oligosaccharides. J Proteome Res 10, 856-868   DOI
22 Yonekawa T, Malicdan MC, Cho A et al (2014) Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice. Brain 137, 2670-2679   DOI
23 Bode L (2012) Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 22, 1147-1162   DOI
24 Chung TW, Kim EY, Kim SJ et al (2017) Sialyllactose suppresses angiogenesis by inhibiting VEGFR-2 activation, and tumor progression. Oncotarget 8, 58152-58162   DOI
25 Kim SK, Seok H, Park HJ et al (2015) Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model. BMC Complement Altern Med 15, 380   DOI
26 Vaarala MH, Hirvikoski P, Kauppila S, Paavonen TK (2012) Identification of androgen-regulated genes in human prostate. Mol Med Rep 6, 466-472   DOI
27 Park SA, Jeong MS, Ha KT, Jang SB (2018) Structure and function of vascular endothelial growth factor and its receptor system. BMB Rep 51, 73-78   DOI
28 Li J, Tian Y, Guo S, Gu H, Yuan Q, Xie X (2018) Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. PLoS One 13, e0191469   DOI
29 Minutoli L, Bitto A, Squadrito F et al (2013) Serenoa repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia. Curr Med Chem 20, 1306-1312   DOI
30 Said MM, Hassan NS, Schlicht MJ, Bosland MC (2015) Flaxseed suppressed prostatic epithelial proliferation in a rat model of benign prostatic hyperplasia. J Toxicol Environ Health A 78, 453-465   DOI
31 Kim JH, Baek MJ, Sun HY et al (2018) Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. PLoS One 13, e0203479   DOI
32 Jun JEJ, Kinkade A, Tung ACH, Tejani AM (2017) 5alpha-Reductase inhibitors for treatment of benign prostatic hyperplasia: A systematic review and metaanalysis. Can J Hosp Pharm 70, 113-119
33 Thomas D, Chughtai B, Kini M, Te A (2017) Emerging drugs for the treatment of benign prostatic hyperplasia. Expert Opin Emerg Drugs 22, 201-212   DOI
34 ten Bruggencate SJ, Bovee-Oudenhoven IM, Feitsma AL, van Hoffen E, Schoterman MH (2014) Functional role and mechanisms of sialyllactose and other sialylated milk oligosaccharides. Nutr Rev 72, 377-389   DOI
35 Bostwick DG, Iczkowski KA (1998) Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin Urol Oncol 16, 118-123
36 Padhani AR, Harvey CJ, Cosgrove DO (2005) Angiogenesis imaging in the management of prostate cancer. Nat Clin Pract Urol 2, 596-607   DOI
37 Ravindranath N, Wion D, Brachet P, Djakiew D (2001) Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 22, 432-443
38 Godoy A, Montecinos VP, Gray DR et al (2011) Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab 300, E263-275   DOI
39 Chung HK, Ryu D, Kim KS et al (2017) Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. J Cell Biol 216, 149-165   DOI
40 Ryu D, Jo YS, Lo Sasso G et al (2014) A SIRT7-dependent acetylation switch of GABPbeta1 controls mitochondrial function. Cell Metab 20, 856-869   DOI
41 Chung TW, Kim SJ, Choi HJ et al (2013) CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth. J Mol Med (Berl) 91, 271-282   DOI